Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer

[Image: see text] The development of orally bioavailable, furanopyrimidine-based double-mutant (L858R/T790M) EGFR inhibitors is described. First, selectivity for mutant EGFR was accomplished by replacing the (S)-2-phenylglycinol moiety of 12 with either an ethanol or an alkyl substituent. Then, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mu-Chun, Coumar, Mohane Selvaraj, Lin, Shu-Yu, Lin, Yih-Shyan, Huang, Guan-Lin, Chen, Chun-Hwa, Lien, Tzu-Wen, Wu, Yi-Wen, Chen, Yen-Ting, Chen, Ching-Ping, Huang, Yu-Chen, Yeh, Kai-Chia, Yang, Chen-Ming, Kalita, Bikashita, Pan, Shiow-Lin, Hsu, Tsu-An, Yeh, Teng-Kuang, Chen, Chiung-Tong, Hsieh, Hsing-Pang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969398/
https://www.ncbi.nlm.nih.gov/pubmed/36749735
http://dx.doi.org/10.1021/acs.jmedchem.2c01434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969398/
https://www.ncbi.nlm.nih.gov/pubmed/36749735
http://dx.doi.org/10.1021/acs.jmedchem.2c01434

Ejemplares similares